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ABSTRACT
Objectives: The aim of the study was to evaluate the prevalence of cellular leiomyomas and partially cellular leiomyomas 
in postoperative samples. 
Material and methods: A total of 2144 cases of uterine leiomyomas were diagnosed in postoperative samples at the 
Department of Obstetrics and Gynecology, RSzS, Radom, Poland, between 1998 and 2014. We analyzed 384 cases which 
were subdivided into 4 groups, taking into account the co-occurrence of leiomyomas and/or endometriosis. The follow-
ing variables were investigated: age, weight, BMI, parity, type of surgical procedure, prevalence of atypical and borderline 
tumor forms, and concomitant malignancy of the reproductive system. 
Results: The prevalence of cellular leiomyomas and partially cellular leiomyomas was estimated at 17.9%. Nulliparous 
patients were significantly more numerous in the subgroups without endometriosis. Concomitant malignancy of the re-
productive system was > 2 fold more commonin the subgroups with endometriosis as compared to the other subgroups.
Conclusions: The fact that cellular leiomyomas have a varying degree of cell atypia, together with clinical observations 
reported in the literature, support the view that cellular leiomyomas and partially cellular leiomyomas can progress to 
malignant leiomyosarcoma (LMS). Hysterectomy and the subsequent follow-up should be the mainstay of therapy for 
cellular leiomyoma. Conservative management (myomectomy) should be recommended only tothose patients who wish 
to preserve their fertility. 
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INTRODUCTION
Leiomyomas are non-epithelial, mesenchymal, be-
nign monoclonal tumors, formed by smooth muscle cells 
of the myoblast or myometrial vessel cell and the stroma 
composed of fibrous connective tissue [1]. Based on the 
histopathological analysis of the extirpated uteruses, leio-
myomas are detected in almost 77% of women in the re-
productive age [2]. Clinically, leiomyomas are diagnosed 
in 25% of all women, 30–40% of women > 40, and 40% of 
women > 50 years of age [3]. Each leiomyoma — regard-
less of it being a part of a cluster or a single uterine lesion 
— develops from a single, initially neutral precursor cell 
which had mutated [4]. Uterine leiomyomas are the most 
common benign lesions in the female population and the 
most frequent pathology of the genital organs in women 
of the reproductive age. The hormone-dependent nature 
of leiomyomas has been demonstrated by their rare occur-
rence after menopause and surgical gonadectomy, as well as 
lack of cases before puberty. In case of uterine leiomyomas, 
it is different from hormone-dependent nature of the myo-
metrium with regard to the quantity and quality of estrogen 
receptors, quantity and quality of progesterone receptors 
— which are several times more numerous in leiomyomatic 
cells, expression and activity of aromatase, and the intensity 
of proliferation and apoptosis [5, 6]. 
Genetic background is one of the identified risk factors 
for the disease [7]. Significantly higher expression of the 
vascular endothelial growth factor A (VEGF-A) was found in 
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the group with family history of leiomyomas [8]. Autosomal 
dominant inheritance has been found, among others, in 
cases of co-occurrence of cutaneous and uterine leiomyo-
mas in as many as 98% of the affected women. The condi-
tion, known as the Reed’s syndrome or MCUL1 (multiple 
cutaneous and uterinae leiomyomata), is associated with the 
mutation of the fumarase encoding gene (an enzyme of the 
Krebs Cycle, localized on chromosome 1) [9]. Cytogenetic 
anomalies, detected in approximately 40% of all leiomyo-
mas, include among others translocation, trisomy, and de-
letion [10, 11]. Chromosomal aberrations are found in the 
cells of submucosal, subserosal, and intramural leiomyomas 
(12%, 29%, and 35%, respectively). Aberrational diversity 
indicates a multitude of genetic mechanisms associated 
with the formation of leiomyomas. Elevated risk for uterine 
sarcomas and higher incidence of postmenopausal tumors 
have been reported for female carriers of the mutation [12]. 
Hoffman et al., are of the opinion that dysregulation of apop-
tosis and proliferation, resulting from genetic abnormalities, 
plays a key role in the development of uterine fibroids [13]. 
Also, results of in vitro tissue studies have demonstrated 
a role of mediating factors such as cytokines and growth 
factors, through which hormones may affect tumor growth. 
Estrogen and progesterone regulate the expression of cy-
tokines and growth factors which modify the activity of 
other transcription factors. In case of dysregulated cytokine 
and growth hormone production, the following processes: 
increasing frequency of cell division, cell hypertrophy, and 
extracellular matrix (ECM) accumulation, individually or all 
together, may be observed [6]. Members of the transforming 
growth factor beta (TGF-β) superfamily play an important 
role in the formation of leiomyomas, both as inhibitors, 
tumor growth stimulators, and regulators of their fibro-
sis. They also affect the tumor microenvironment as immu-
nosuppressive factors and angiogenesis stimulators [14, 15]. 
Their activity — especially that of TGF-β3 — was confirmed 
in the transformation of a normal uterine muscle cell to 
its malignant phenotype. Overexpression of TGF-β3 plays 
a vital role in the formation of ECM, characteristic for uter-
ine fibroids [16, 17]. Proteins from the BMP-1/mTLD (bone 
morphogenetic protein 1/mammalian tolloid) subfamilyare 
important regulators of ECM formation as well as formation 
of the antiangiogenic factor from prelecan — a component 
of the basement membrane [1].
Cellular fibroids are the most common (5%) among the 
numerous histological subtypes of leiomyomas [18]. Their 
histopathological examination revealed cell abundance, 
with a small component of connective elements, little or 
no atypia, absence of coagulative necrosis, and the mitotic 
count of < 5/10 HPF (microscope field of view at 40× mag-
nification). Immunohistochemical analysis — for desmin, 
CD, H-caldesmon — are used to differentiate cellular leio-
myomas from stromal tumors of the uterine corpus and 
leiomyosarcomas (LMS). At present, it is believed that in 
the absence of coagulative necrosis, tumors with < 10 mito-
ses/10 HPF, without cell polymorphism, have a good prog-
nosis, whereas tumors with >10 mitoses/10 HPF, without cell 
polymorphism, are malignant.Malignant transformation is 
suspected in case of cellular leiomyomas with the mitotic 
index of ≥ 5 and accompanying atypia [19]. Nevertheless, 
the literature emphasizes the challenge of unambiguous 
classification and histopathologic evaluation of various 
subtypes of leiomyomas, as well as the prognosis for their 
clinical course.
OBJECTIVES
The aim of the study was to evaluate the prevalence of 
cellular leiomyomas (CL) and partially cellular leiomyomas 
in postoperative samples of uterine leiomyomas collected 
over the course of 17 years. 
MATERIAL AND METHODS
A total of 2144 cases of uterine leiomyomas were dia- 
gnosed in postoperative material obtained during surger-
ies and procedures performed at the Department of Ob-
stetrics and Gynecology, RSzS, Radom, Poland, between 
1998 and 2014. Uterine leiomyomas and leiomyomas with 
coexisting endometriosis were detected in 1308 (61.00%)
and 836 (39.00%) of the samples, respectively. 
Patients were deemed eligible for surgery based on 
gynecological and ultrasound examinations, as well as his-
topathological evaluation of uterine scrapings. The material 
for the study consisted in surgical protocols, results of his-
topathologic evaluations (diagnostic, preliminary and final) 
from the medical charts, hospital charts, results of laboratory 
studies, and data on additional treatments and check-ups 
at out-patient ob-gyn and oncology clinics.
The final diagnosis was made at the Department of 
Pathomorphology, RSzS, Radom, Poland. Microscopic evalu-
ation of the mitotic index, presence of atypia and tumor 
necrosis was performed. Clinic analysis was conducted in 
the 384 cases with confirmed cellular leiomyomas and par-
tially cellular leiomyomas. The following 4 subgroups were 
identified:
 Ū group I — cellular leiomyoma (CL) (N = 92);
 Ū group II — CL with endometriosis (N = 32);
 Ū group III — partially cellular leiomyomas and/or CL 
with leiomyoma (N = 152); 
 Ū group IV — partially cellular leiomyomas and/or CL 
with leiomyoma and endometriosis (N = 108).
Partially cellular leiomyomas were also included into 
the analysis, bearing in mind that each such case might in 
fact be a preliminary variant form of CL, which is supported 
by their known coexistence with malignant tumors of the 
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genital tract, especially LMS. The groups with concurrent 
endometriosis of the uterine corpus were analyzed sepa-
rately due to significantly higher prevalence of malignant 
neoplasms of the genital tract among these cases. 
The analysis took into account patient age, weight, BMI, 
parity (delivery, miscarriage, ectopic pregnancy), the need 
for blood and blood products, different coexisting histo-
pathologic variants of cellular leiomyomas, coexistence of 
leiomyomas and/or endometriosis, or malignant tumors 
with cellular leiomyomas, and type of surgery (including 
myomectomy during cesarean section). The results are pre-
sented in Tables 1–7. 
Statistical analysis was performed using the Gretl soft-
ware (shareware, free license). ANOVA was used to deter-
mine the statistical significance of the differences between 
the groups of patients, while the t-student test verified 
intergroup differences. The p-value of < 0.05 was considered 
as statistically significant.
RESULTS
Mean patient age in the four subgroups was 
47.7 years. Statistically significant differences were observed 
between women from groups II and III, as well as III and IV 
(Tab. 1).
Differences in weight did not reach statistical signifi-
cance but the difference in BMI was significantly different 
in patients from groups I and II (Tab. 2). 
Obstetric data (delivery, miscarriage, ectopic pregnancy) 
are presented in Table 3. Statistically significant differences 
— only with regard to the number of deliveries — were 
found between women from groups I and II, II and III, as 
well as III and IV. 
Packed red blood cells and fresh frozen plasma were 
needed in 12 (9.7%) women from groups I and II [N = 124], 
but in as many as 47 (18.1%) from groups III and IV [N = 260] 
(Tab. 4).
The prevalence of the different variants of CL, defined 
on the basis of histopathological diagnosis, is presented in 
Table 5. Table 6 includes detailed data on type, route and 
mode of the procedure/surgery in all groups of patients, 
while data on coexisting malignant tumors of the genital 
tract are presented in Table 7.
Table 8 includes detailed numeric data (with percent-
ages) on the prevalence rates of CL and partially cellular 
leiomyoma among the 2144 women undergoing proce-
dures and surgeries due to uterine leiomyomas.
DISCUSSION
Among the 2144 women with uterine leiomyomas con-
firmed on histopathology, the total prevalence rate for CL 
and partially cellular leiomyomas was 17.9% (Tab. 8). Out of 
them, CL was found in 4.3% of the women. That rate reached 
5.8% when CL cases with coexisting endometriosis (1.5%) 
were taken into account, and 9.4% when CL cases with 
coexisting leiomyomas and/or partially cellular leiomyo-
mas (3.6%) were included. The 9.4% rate is 2-fold higher as 
compared to the available literature. 
In our study, there were 10 (2.6%) cases of cellular leio-
myomas in the uterine cervix, including 3 cases of CL and 7 of 
partially cellular leiomyomas. In one woman, we simultane-
ously detected CL in the uterine cervix and partially cellular 
leiomyoma in the uterine corpus. The literature reports the 
prevalence rate for leiomyomas in the uterine cervix to be 
approximately 4–7% [20].
Table 1. Age of patients with leiomyomas
Groups 1–4
Mean age: 47.66 Cellular leiomyoma (CL) CL with endometriosis 
Partially cellular leiomyoma  
and/or CL with leiomyoma 
Partially cellular leiomyoma  
and/or CL with leiomyoma  
and endometriosis 
Mean age (in years) 47.24 50.78 45.97 49.47
Range 26–76 36–68 31–75 33–70
SD 9.52 9.24 8.76 8.14
Table 2. Weight and BMI in the groups of women with CL and partially cellular leiomyoma
Groups 1–4
Weight mean: 70.72
BMI mean: 26.66
Cellular leiomyoma (CL) CL with endometriosis Partially cellular leiomyoma and/or CL with leiomyoma 
Partially cellular leiomyoma 
and/or CL with leiomyoma 
and endometriosis 
Mean
Range
SD
69.21
52–118
12.03
75.25
52–140
19.42
70.52
53–117
13.31
70.95
48–122
13.18
Mean 
Range
SD 
25.86
19.16–38.09
4.05
28.47
21.33–44.19
5.81
26.63
17.30–40.46
4.67
26.85
19.37–39.39
4.20
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Among pregnant women, the prevalence rate for uterine 
leiomyomas has been estimated at 1.5–7.5%. Myomectomy 
during cesarean section is indicated only in selected cases 
[21]. In our study, myomectomy was performed in 84 (21.9%) 
women. Nine (2.3%) myomectomies were performed dur-
ing cesarean section, including 4 cases of CL (Tab. 6). To the 
best of our knowledge, the literature offers no reports on 
the prevalence of CL removed during cesarean delivery. 
Also, data on the coexistence of endometriosis with cellular 
leiomyomas of the uterus are unavailable — in our study, 
the rate was 36.5%. Concomitant endometriosis and leio-
myomatosis was reported by Taran et al., in 20% out of the 
1955 women undergoing surgery [22]. 
According to the literature, mean age of patients with 
postoperative diagnosis of cellular leiomyomas is lower as 
compared to women undergoing surgery due to leiomyo-
mas. In our study, mean patient age was calculated at 47.7%, 
and was higher than reports from Guan et al., and Taran et 
al., 45.3 and 44.7 years, respectively [18, 23]. 
Mean weight in our study was 70.7 kg, and no significant 
differences were found between the four subgroups. A statisti-
cally significant difference in BMI was observed only between 
patients from groups I and II (Tab. 2). Apart from ethnicity, 
risk-promoting factors for the development of myomas in-
clude age, obesity, and genetic factors. Taran et al., found a BMI 
of 28.3 in 99 women with confirmed cellular myomas [23].
Obstetric data (delivery, miscarriage, ectopic pregnancy) 
are presented in Table 3. Out of 336 parous women, mean par-
ity was 2.3 (ranging from 2.2 to 2.5 in the studied groups). 
Interestingly, the rate of nulliparous women (16.8%) in groups 
I and III — only with uterine leiomyomas, without endome-
triosis (N-244) was over 3-fold higher than the rate reported 
in groups II and IV (5%) — uterine myomas with concomitant 
endometriosis of the uterine corpus (N-140). Additionally, 
lower rate of cesarean sections was observed in women from 
groups II and IV — with concomitant endometriosis. Taran et 
al., in some of the cited sources, found a higher number of 
cesarean sections in women with adenomyosis [22]. 
Table 7. Prevalence of malignant tumors in women with cellular leiomyomas
Subgroups (1–4) with uterine leiomyomas  
(N = 384)
Uterine malignancy 
Ovarian cancer Breast cancer Total (%)Corpus Cervix
No. No. No. (%)
Cellular leiomyoma (CL), N = 92 3 1 2 6 (6.5)
CL with endometriosis, N = 32 6 1 [1] 7 (21.9)
Partially cellular leiomyoma and/or CL  
with leiomyoma, N = 152 3 [1] 1 4 (2.6)
Partially cellular leiomyoma and/or CL  
with leiomyoma and endometriosis, N = 108 4 1 [1] 3 8 (7.4)
Co-occurrence in different organs 16 [1] 2 [1] 6 1 [1] 25 (6.5)
[ ] — malignant neoplasms treated before surgery or diagnosed preoperatively
Table 8. Cellular leiomyomas (CL) and partially cellular leiomyomas among the 2144 cases with diagnosed uterine leiomyomas
Subgroups with uterine 
leiomyomas 
No. and prevalence rate
Cellular leiomyomas (CL) (N = 201) 
PR out of 384: –52.3, PR out of 2144: –9.4
Partially cellular leiomyomas 
(N = 183)CL 
(N = 197) 
CL — with partially  
cellular leiomyomas
 (N = 4)
No. PR out of 384
PR out 
of 2144 No.
PR out 
of 384
PR out 
of 2144 No.
PR out 
of 384
PR out 
of 2144
Group 1, N = 92 (24.0%) 92 24.0 4.3
Group 2, N = 32 (8.3%) 32 8.3 1.5
Groups 1 and 2, N = 124 (32.3%) 124 32.3 5.8
Group 3, N = 152 (39.6%) 47 12.2 2.2 2 0.5 0.09 103 26.8 4.8
Group 4, N = 108 (28.1%) 26 6.8 1.2 2 0.5 0.09 80 20.9 3.7
Groups 3 and 4, N = 260 (67.7%) 73 19.0 3.4 4 1.0 0.2 183 47.7 8.5
Total 197 51.3 9.2 4 1.0 0.2 183 47.7 8.5
PR — prevalence rate
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The risk for developing uterine leiomyomas according 
to various authors is 2-fold higher in case of infertility, and 
5-fold lower in multiparas (> 5) as compared to nulliparas. The 
literature reports the prevalence rate for uterine fibroids in 
infertile subjects to range between 1% and 2.4%. The correla-
tion between infertility and uterine leiomyomas remains to be 
fully elucidated. Randomized studies are necessary to deter-
mine the possibility of uterine leiomyomas being the cause 
of infertility [24]. In our study, the higher rate of nulliparous 
women in groups without concomitant endometriosis, in the 
majority of cases 141 (57.8%) with CL, may be associated with 
the reported higher weight of the fibroids, which might be 
responsible for infertility or miscarriage [23].
Dyląg et al., concluded that blood and its products may 
be used in patients with the diagnosis of leiomyoma, treated 
at the Division of Obstetrics and Gynecology of a clinical and 
district hospital — 6.6% and 8.2%, respectively [25]. In our 
study, the high rate (15.4%) of blood transfusions among 
women undergoing surgery for uterine leiomyomas was 
undoubtedly connected with the higher weight of CL — re-
ported in the literature — resulting in surgical challenge and 
consequent more perioperative blood loss [23].
The distribution of various CL histopathological variants 
has been presented in detail in Table 5. Histopathological 
results include partially malignant CL, CL with atypia, and 
borderline malignant CL. The available literature mentions 
borderline CL and transformation to LMS also in other or-
gans of the genital and urinary tract [11, 18].
Numerous authors concluded that cellular leiomyomas 
possess a separate — as compared to typical leiomyomas 
— clinical phenotype and common genetic features with 
LMS [23, 26, 27]. Deletion of chromosome 1p — charac-
teristic of LMS — was also found in the CL subtype in 23% 
of the cases. That genetic modification is associated with 
potentially malignant nature of cellular leiomyomas. The 
presence of that pathology is an important element in the 
decision-making process about conservative treatment and 
clinical supervision [27]. 
Our histopathological analysis detected cases of border-
line CL (Tab. 5). Additionally, partially cellular leiomyoma in 
the right uterus and LMS in the left uterus were found in one 
patient with two uteruses and vaginas (R.M., aged 71). Also, 
our clinical observations and histopathology results suggest 
the possibility of CL transformation to LMS. According to the 
available literature, that risk ranges from 0.1% to 0.8% [28].
Two cases of intravenous leiomyomatosis, which is 
a particularly rare type of myometrial invasion, were found 
among our patients. Du et al., reported a 33.3% rate of cellu-
lar leiomyomatosis in their study of intravenous leiomyoma-
tosis [29]. Hemorrhagic cellular leiomyoma was observed in 
cases of myomectomy performed during a cesarean section. 
The recurrence rates among patients after myomectomy 
were reported by various studies, e.g. 28.6% and 8% [18, 
23]. Also, recurrence was also reported after total radical 
hysterectomy [26, 30].
Implantation metastases — even after several decades 
since myomectomy or hysterectomy — have been report-
ed also in cases of CL. Their incidence is similar to that of 
leiomyoma. The most common metastatic sites include the 
lungs, but also skeletal muscles, heart, bone marrow, and the 
peritoneal cavity — often, they pose a direct threat to the 
patient life. A case of death due to malignant transformation 
after surgery was reported in a patient with diagnosed CL 
[23, 26, 30]. Dong et al., reported a case of cellular leiomyoma 
accompanied by Pseudo-Meigs syndrome [31]. The above-
mentioned clinical observations indicate that CL should not 
be treated as a tumor with a benign course [26, 30]. 
In our study, a total of 299 (77.8%) hysterectomies 
— with lymphadenectomy, simple and subtotal — were 
performed in 13 (3.4%), 175 (45.5%) and 111 (28.9%) women 
(Tab. 6). In case of cellular leiomyomas, high rates of hyster-
ectomies were connected with the recent recommendations 
of more radical surgical treatment. Earlier studies claimed 
that the risk for malignant transformation is no indication 
for hysterectomy. Concomitant malignant tumors of the 
genital tract were found in 26 (6.8%) of the patients under-
going surgery, out of them 16 (4.2%) in the uterine corpus, 
including 11 (2.9%) with CL and 5 (1.3%) with partially cel-
lular leiomyoma (Tab. 7). 
Significant differences were found in the prevalence of 
malignant tumors of the genital tract between women with 
and without coexisting endometriosis. In our study, endo-
metriosis was found in 140 (36.5%) cases: 60 (29.9%) among 
201 patients with CL and 80 (43.7%) among 183 patients 
with partially cellular leiomyoma. Taran et al., observed con-
comitant endometriosis in 8.1% of the women with CL [23].
Malignant transformation of endometriosis was reported 
already in 1925 by Sampson, mainly in cases of ovarian can-
cer, but also other fragments of the genital tract, including 
endometrial adenocarcinomas [32]. In our study, CL and par-
tially cellular leiomyoma with concomitant endometriosis 
of the uterine corpus — concomitant malignancy — were 
found in 10.7% of the 140 women undergoing surgery in 
groups II and IV, whereas in groups I and III — without en-
dometriosis of the uterine corpus — the rate was 4.5% of 
the 244 women. As for the malignancy of the uterine corpus, 
the rates were 7.1% and 2.5% in the same groups, while in 
the groups with concomitant endometriosis of the uterine 
corpus the values more than doubled (Tab. 7). 
In light of the borderline pathological nature of CL and 
reported cases of malignant transformation of other rare his-
tological subtypes of leiomyomas, e.g. lipoleiomyoma, recent 
years have seen a visible shift in opinions of many researchers, 
who postulate a longer clinical supervision of patients treated 
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for CL. Hysterectomy, followed by clinical supervision, ought 
to become a standard [18, 30]. Strict clinical supervision after 
conservative management is recommended at the very least 
for women in the reproductive age who wish to preserve their 
fertility [26]. Thus, it seems prudent to resort to conservative 
management only in the following cases: patient’s wish to 
conceive, lack of consent for surgery, or specific circumstances 
when surgery is deemed impossible [18, 26]. 
Attempts to use genetic therapy for treating uterine 
leiomyomas have also been made. The results of studies on 
animal models, using genetic therapy to inactivate the estro-
gen receptor which leads to cell apoptosis and modulates 
ECM proliferation of the leiomyoma, generated promising 
results [33, 34].
Interdisciplinary cooperation of various specialists, in-
cluding scholars in the field of basic research, is required in 
order to advance the diagnostic process and treatment of 
uterine leiomyomas, including cellular leiomyomas.
CONCLUSIONS
Histopathology reports of CL cases with varying degrees 
of atypia, combined with the collected clinical data, in the 
literature indicate the possibility of malignant transforma-
tion of cellular leiomyomas and partially cellular leiomyo-
mas to leiomyosarcomas. Hysterectomy, followed by clinical 
supervision, ought to become a standard in the treatment 
of cellular leiomyomas. Conservative management — myo- 
mectomy — should be reserved for patients who wish to 
preserve their fertility, refuse surgical treatment, or in cases 
when surgery is deemed impossible.
REFERENCES
1. Auguściak-Duma A, Sieroń AL. Molekularna charakterystyka guzów 
leiomyoma uteri na przykładzie wybranych składników macierzy poza-
komórkowej. Postępy Hig Med Dośw. 2008, 62, 148–165.
2. Canevari RA, Pontes A, Rosa FE, [et al.]. Independent clonal origin of 
multiple uterine leiomyomas that was determined by X chromosome 
inactivation and microsatellite analysis. Am J Obstet Gynecol. 2005, 193, 
1395–1403.
3. Fernandes H, Naik CN, Swethadri GK, [et al.]. Pure lipoma of the uterus: 
A rare case report. Indian J Pathol Microbiol. 2007, 50, 800–801.
4. Ligon AH, Morton CC. Genetics of uterinae leiomyoma. Genes Chromo-
somes Cancer. 2000, 28, 235–245.
5. Dębski R, Kotarski J, Paszkowski T, [et al.]. Stanowisko Zespołu Ekspertów 
Polskiego Towarzystwa Ginekologicznego w sprawie zastosowania 
selektywnych modulatorów receptora progesteronowego (SPRM) 
w leczeniu mięśniaków macicy. Ginekol Pol. 2012, 83, 555–557.
6. Sozen I, Arici A. Interaction of cytokines, growth factors, and the extra-
cellular matrix in the cellular biology of uterinae leiomyomata. Fertil 
Steril. 2002, 78, 1–12.
7. Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clini-
cians need to know. Obstet Gynecol. 2006, 107, 917–921.
8. Chang CC, Hsieh YY, Lin WH, [et al.]. Leiomyoma and vascular endothelial 
growth factor gene polymorphisms: a systematic review. Taiwan J Obstet 
Gynecol. 2010, 49, 247–253.
9. Toro JR, Nickerson ML, Wei MH, [et al.]. Mutations in the fumaratehydra-
tase gene causa hereditary leiomyomas and renal cell cancer in families 
in North America. Am J Hum Genet. 2003, 73, 95–106.
10. Czapczak D, Markowska A, Piątkowska M, [et al.]. Nosicielstwo mutacji 
w eksonie 6 genu NBS1 a ryzyko zachorowania na mięśniaki macicy. 
Nowotwory J Oncol. 2011, 61, 109–113.
11. Hodge JC, Pearce KE, Clayton AC, [et al.]. Uterine cellular leiomyomata 
with chromosome 1p deletions represent a distinct entity. Am J Obstet 
Gynecol. 2014, 210, 527, e1–e7.
12. Lobel MK, Somasundaram P, Morton CC. The genetic heterogeneity of 
uterine leiomyomata. Obstet Gynecol Clin North Am. 2006, 33, 13–39.
13. Hoffman PJ, Milliken DB, Gregg LC, [et al.]. Molecular characterization 
of uterine fibroids and its complication for underlying mechanisms of 
pathogenesis. Fertil Steril. 2004, 82, 639–649.
14. Luo X, Ding L, Xu J, [et al.]. Gene expression profiling of leiomyoma and 
myometrial smooth muscle cells in response to transforming growth 
factor. Endocrinology. 2007, 146, 1097–1118.
15. Laping NJ, Everitt JI, Frazier KS, [et al.]. Tumor-specific efficacy of 
trans forming growth factor-beta RI inhibition in Eker rats. Clin Cancer 
Res. 2007, 13, 3087–3099.
16. Halder SK, Goodwin JS, Al-Hendy A. 1,25-Dihydroxyvitamin D3 reduces 
TGF-β3-induced fibrosis-related gene expression in human uterine 
leiomyoma cells. J Clin Endocrinol Metab. 2011, 96, E754–E762.
17. Norian JM, Malik M, Parker CY, [et al.]. Transforming growth factor beta3 
regulates the versican variants in the extracellular matrix-rich uterine 
leiomyomas. Reprod Sci. 2009, 16, 1153–1164.
18. Guan R, Zheng W, Xu M. A retrospective analysis of the clinicopathologic 
characteristics of uterine cellular leiomyomas in China. Inter J Gynecol 
Obstet. 2012, 118, 52–55.
19. Madej P, Madej JA. Patomorfoza mięśniaków macicy u kobiet. Gin Pol 
Med. Project. 2008, 3, 32–42.
20. Taran FA, Stewart EA, Brucker S. Adenomyosis: Epidemiologie, 
risikfaktoren, klinisches erscheinungsbild sowie chirurgische und 
interventionelle alternative zur hysterectomie. Geburtsh Frauenheilk. 
2013, 73, 924–931.
21. Taran FA, Weaver AL, Gostout BS, [et al.]. Understanding cellular leiomyo-
mas: a case-control study. Am J Obstet Gynecol. 2010, 203, 109, e1–e6.
22. Farguhar C, Arroll B, Ekeroma A, [et al.]. Anevidence-based guideline 
for the management of uterine fibroids. Aust NZJ Obstet Gynaecol. 
2001, 41, 125–140.
23. Dyląg S, Kucharz EJ. Wykorzystanie krwi i jej składników w dwóch od-
działach ginekologiczno-położniczych szpitali województwa śląskiego 
w latach 1996–2002. Pol Merk Lek. 2011, 30, 195–2001.
24. Musierowicz A, Chilimoniuk M, Matejczuk A, [et al.]. Przypadek zezło-
śliwiałego mięśniaka gładkokomórkowego pęcherza moczowego. Urol 
Pol. 1978, 3, 3.
25. Guraslan H, Senturk MB, Helvacioglu C, [et al.]. Recurent cellular leio-
myoma 10 years after total abdominal hysterectomy. J Obstet Gynaecol. 
2015, 35, 854–855.
26. Markowska A, Słomko Z. Mięśniaki macicy. In: Słomko Z (ed.). Gineko-
logia. PZWL, Warszawa 2008, 148–165.
27. Du J, Zhao X, Guo D, [et al.]. Intravenous leiomyomatosis of the uterus: 
A clinicopathologic study of 18 cases, with emphasis on early diagnosis 
and appropriate treatment strategies. Hum Pathol. 2011, 42, 1240–1246.
28. Rothmund R, Kurth RR, Łukasińska NM, [et al.]. Clinical and pathological 
characteristics, pathological reevaluation and recurrence patterns of 
cellular leiomyomas: a retrospective study in 76 patients. Eur J Obstet 
Gynecol Reprod Biol. 2013, 171, 358–361.
29. Dong R, Jin C, Zhang Q, [et al.]. Cellular leiomyoma with necrosis and 
mucinous degeneration presenting as pseudo-Meigs' syndrome with 
elevated CA 125. Oncol Rep. 2015, 33, 3033–3037.
30. Pośpiech-Gąsior K. Wpływ mięśniaków macicy na przebieg ciąży, porodu 
oraz połogu. Rozprawa doktorska. Kraków 2011. Pozyskano z dl.cm-uj.
krakow.pl:8080/Content/3402.
31. Emerich J. Operacyjne leczenie mięśniaków. In: Markowska J (ed.). Mię-
śniaki macicy. Wydawnictwo MedPharm Polska, Wrocław 2008, 73–83.
32. Markowska J. Endometrioza a procesy nowotworowe. In: Radowicki S, 
Szyłło K (eds.). Endometrioza. Diagnostyka i leczenie. Wydawnictwo Edra 
Urban & Partner, Wrocław 2016, 249–252.
33. Al-Hendy A, Salama S. Gene therapy and uterine leiomyoma: a review. 
Human Reprod Update. 2006, 12, 385–400.
34. Hassan MH, Salama SA, Zhang D, [et al.]. Gene therapy targeting leio-
myoma: adenovirus-mediated delivery of dominant-negative estrogen 
receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril. 
2010, 93, 239–250.
